Clinical Trial Search

Primary: H01: All Cause Mortality — 244; 218 participants — p=0.12

Primary: Efficacy Endpoint: The Percent of Patients Off Class I and/or III Antiarrhythmic Drugs and Out of Atrial Fibrillation as Determined by 24 Hour Holter Recording Conducted…

Primary: Septal Thickness Measured Before Cardiopulmonary Bypass — 22.9; 22.5 millimeters

Primary: Efficacy Endpoint: The Percent of Patients Off Class I or III Antiarrhythmic Drugs and Out of AF as Determined by 24 Hour Holter Recording at 9 Months — 42.6 percentage…

Primary: Incidence of First MACE During Active Follow-up Period. — 80; 89 Participants — p=0.47

Primary: Short-term End Point — 61; 77 participants

Primary: Myocardial Defect Perfusion — 15.76; 15.38; 2.08; 3.85 Percentage of Myocardial Perfusion

Primary: Incidence of Documented Post-operative Atrial Fibrillation — 17; 2 Participants

Primary: Number of Participants Who Experienced Adverse Events Possibly Related to Study Intervention — 0; 6 Participants

Primary: Primary Safety Endpoint — 0; 0; 4.2; 0 percentage of participants

Primary: Technical Success (Graft Patency) in a MICS Approach — 100 percentage of grafts

Primary: Postoperative Complications — 52; 72 numbers of complications

Primary: Number of Late Adverse Events Divided by Late Patient Years (Expressed as a Percentage) for the INTUTY Valve Implanted Cohort — 3.9; 0.9; 0.6; 0.3 Percentage of…

Primary: Number of Participants With Device and Procedure Related Serious Adverse Events — 11; 5 Participants

Primary: Percentage of Participants With Interventional Procedures Successfully Completed — 10; 20 Participants

Primary: Incidence of Postoperative Atrial Fibrillation — 5; 4; 5 participants

Primary: Primary Safety Endpoint — 3.9; 3.6 percentage of participants

Primary: Percent of Early Adverse Events — 1.7; 1.0; 4.5; 0.0 Percentage of subjects

Primary: Cardiac Index — 3.39; 3.42; 3.23 L/min/m2

Primary: Intraoperative and Postoperative Transfusions — 2.43; 2.97; 4.42; 3.50 units of blood per participant — p=0.354

Primary: Feasibility Evaluation and Major Cardiac Adverse Events Related to Transcoronary Infusion of Cardiac Progenitor Cells — 0; 0 participants

Primary: Accuracy (FTF Decision on Patient Disposition vs. V-visit Decision on Patient Disposition) — 89 percentage of agreement

Primary: Number of Subjects With Adverse Events — 7; 4 Participants

Primary: Time-based Score — 553; 127; 143 score on a scale

Primary: Number of Attempts for Successful Central Venous Cannulation — 1.29 Attempts

Primary: Number of Participants Free of Adverse Effects at 6 Months Post Procedure — 15 Participants

Primary: Rate of Device Related Serious Adverse Events — 0 Number of participants

Primary: Acute Lung Injury After Cardiac Surgery — 20 participants — p=<0.05

Primary: Major Serious Adverse Events (MSAEs) and Serious Adverse Device Effects (SADE) — 3; 1 Participants

Primary: Number of Participants With Major Serious Adverse Events and Serious Adverse Device Effects — 2; 1; 2; 4 Participants